Cutia Therapeutics(HK:2487)
HK$0.68-0.01 (-0.73%)
HK:2487
Cutia Therapeutics financials statements
HK$0.68
At close:-0.01 (-0.73%)
Want to see HK:2487 full AI Analyst Report?
Cutia Therapeutics (2487) Ratios
2 Followers
Cutia Therapeutics Ratios
HK:2487's free cash flow for Q2 2026 was ¥-108.57M. For the 2026 fiscal year, HK:2487's free cash flow was decreased by ¥-1.49M and operating cash flow was ¥-107.08M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.87 | 3.36 | 5.56 | 14.80 | 72.82 |
| Quick Ratio | 3.73 | 3.13 | 5.38 | 14.54 | 72.72 |
| Cash Ratio | 0.98 | 1.19 | 1.86 | 6.02 | 10.55 |
| Solvency Ratio | -0.73 | -0.96 | -5.37 | -0.20 | -0.14 |
| Operating Cash Flow Ratio | -1.08 | -1.37 | -1.50 | -3.05 | -8.31 |
| Short-Term Operating Cash Flow Coverage | -1.74 | -2.08 | -2.95 | 0.00 | 0.00 |
| Net Current Asset Value | ¥ 638.01M | ¥ 668.61M | ¥ 1.06B | ¥ -1.55B | ¥ -883.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.23 | 0.14 | 0.04 | 0.02 |
| Debt-to-Equity Ratio | 0.36 | 0.33 | 0.18 | -0.04 | -0.03 |
| Debt-to-Capital Ratio | 0.26 | 0.25 | 0.15 | -0.05 | -0.03 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.05 | 0.04 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.48 | 1.43 | 1.27 | -1.16 | -1.89 |
| Debt Service Coverage Ratio | -1.51 | -1.92 | -14.32 | -309.72 | -553.18 |
| Interest Coverage Ratio | -32.62 | -41.91 | -120.54 | -178.94 | -321.98 |
| Debt to Market Cap | 0.19 | 0.14 | 0.07 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.99 | 1.08 | 0.81 | 0.70 | 0.34 |
| Net Debt to EBITDA | -0.20 | 0.15 | 0.12 | 0.77 | 0.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 58.25% | 51.31% | 51.60% | 69.84% | 79.00% |
| EBIT Margin | -91.81% | -165.06% | -1423.66% | -4875.14% | -15653.68% |
| EBITDA Margin | -78.90% | -154.03% | -1392.79% | -4708.67% | -15173.16% |
| Operating Profit Margin | -91.81% | -162.78% | -392.12% | -2720.43% | -8831.45% |
| Pretax Profit Margin | -101.20% | -155.15% | -1426.91% | -4890.34% | -15681.11% |
| Net Profit Margin | -101.20% | -155.15% | -1426.91% | -4890.34% | -15681.11% |
| Continuous Operations Profit Margin | -101.20% | -155.15% | -1426.91% | -4890.34% | -15681.11% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 110.23% | 95.31% | 363.89% | 179.76% | 177.56% |
| Return on Assets (ROA) | -26.03% | -31.14% | -115.06% | -38.42% | -21.38% |
| Return on Equity (ROE) | -38.41% | -44.51% | -145.57% | 44.60% | 40.43% |
| Return on Capital Employed (ROCE) | -29.76% | -42.54% | -37.17% | -22.58% | -12.20% |
| Return on Invested Capital (ROIC) | -25.31% | -35.13% | -33.88% | -22.43% | -12.17% |
| Return on Tangible Assets | -26.19% | -31.34% | -115.58% | -38.45% | -21.40% |
| Earnings Yield | -25.21% | -22.24% | -73.97% | -35.83% | -22.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.83 | 2.73 | 2.17 | 8.49 | 4.09 |
| Payables Turnover | 9.13 | 10.62 | 3.28 | 0.00 | 1.28 |
| Inventory Turnover | 3.96 | 1.82 | 1.47 | 0.17 | 0.24 |
| Fixed Asset Turnover | 1.64 | 1.27 | 0.61 | 0.05 | 0.03 |
| Asset Turnover | 0.26 | 0.20 | 0.08 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.44 | 0.29 | 0.12 | 0.01 | 0.00 |
| Cash Conversion Cycle | 251.41 | 299.57 | 305.51 | 2172.06 | 1341.96 |
| Days of Sales Outstanding | 199.12 | 133.71 | 168.41 | 42.97 | 89.19 |
| Days of Inventory Outstanding | 92.26 | 200.24 | 248.29 | 2129.10 | 1538.46 |
| Days of Payables Outstanding | 39.97 | 34.37 | 111.18 | 0.00 | 285.69 |
| Operating Cycle | 291.38 | 333.94 | 416.69 | 2172.06 | 1627.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.88 | -1.44 | -1.25 | -2.95 | -2.00 |
| Free Cash Flow Per Share | -0.92 | -1.53 | -1.43 | -4.64 | -2.32 |
| Dividend Paid and CapEx Coverage Ratio | -22.53 | -17.25 | -6.82 | -1.75 | -6.18 |
| Capital Expenditure Coverage Ratio | -22.53 | -17.25 | -6.82 | -1.75 | -6.18 |
| Operating Cash Flow Coverage Ratio | -0.91 | -1.38 | -1.56 | -4.36 | -6.03 |
| Operating Cash Flow to Sales Ratio | -0.86 | -1.58 | -2.77 | -20.78 | -78.45 |
| Free Cash Flow Yield | -22.46% | -24.03% | -16.47% | -23.95% | -12.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.96 | -4.50 | -1.35 | -2.79 | -4.48 |
| Price-to-Sales (P/S) Ratio | 4.01 | 6.98 | 19.29 | 136.50 | 702.11 |
| Price-to-Book (P/B) Ratio | 1.52 | 2.00 | 1.97 | -1.24 | -1.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.45 | -4.16 | -6.07 | -4.18 | -7.70 |
| Price-to-Operating Cash Flow Ratio | -4.65 | -4.40 | -6.96 | -6.57 | -8.95 |
| Price-to-Earnings Growth (PEG) Ratio | 0.15 | 0.06 | 0.18 | -0.04 | 0.00 |
| Enterprise Value Multiple | -5.28 | -4.38 | -1.27 | -2.13 | -4.06 |
| Enterprise Value | 1.40B | 1.89B | 2.43B | 1.14B | 1.25B |
| EV to EBITDA | -5.28 | -4.38 | -1.27 | -2.13 | -4.06 |
| EV to Sales | 4.17 | 6.74 | 17.62 | 100.27 | 615.46 |
| EV to Free Cash Flow | -4.62 | -4.02 | -5.55 | -3.07 | -6.75 |
| EV to Operating Cash Flow | -4.83 | -4.26 | -6.36 | -4.83 | -7.85 |
| Tangible Book Value Per Share | 2.70 | 3.14 | 4.39 | -15.58 | -9.89 |
| Shareholders’ Equity Per Share | 2.68 | 3.17 | 4.42 | -15.57 | -9.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.02 | 0.91 | 0.45 | 0.14 | 0.03 |
| Net Income Per Share | -1.03 | -1.41 | -6.43 | -6.94 | -3.99 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.10 | 0.94 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.44 | 0.71 | 1.57 | 15.90 | 54.25 |
| SG&A to Revenue | 1.06 | 1.07 | 0.34 | 1.12 | 6.07 |
| Stock-Based Compensation to Revenue | 0.08 | 0.25 | 0.96 | 8.80 | 20.17 |
| Income Quality | 0.85 | 1.02 | 0.19 | 0.42 | 0.50 |
Currency in CNY
